A NOVEL APPROACH TO VASCULAR CLOSURE

A new degree of freedom for treating vasculature
Utilizing an active Implant for a super-selective vascular closure

About us

LuSeed provides the interventional vascular world with a  game changing approach to short and long-term vascular closure. LuSeed’s technology introduces a proprietary tissue enhancing method designed for controlled vascular remodeling robust tissue growth
This first-in-category platform technology positions LuSeed as a potential first mover, in markets involving high demand for safe and precise vascular remodeling tool

The first indication that LuSeed tackles is Cerebral aneurysms, which is a leading cause for haemorrhagic stroke, and is prevalent in 10-15 million Americans.
 Aneurysm Ruptures, which are evident in 30% of all cases, may cause a cerebral haemorrhage with 50% survival rate. Current endovascular treatments for Wide Neck Aneurysms, which comprise 40% of all cases and are most difficult to treat, do not present a balanced safety and efficacy profile.

LuSeed provides the interventional vascular world with a  game changing approach to short and long-term vascular closure. LuSeed’s technology introduces a proprietary tissue enhancing method designed for controlled vascular remodeling robust tissue growth
This first-in-category platform technology positions LuSeed as a potential first mover, in markets involving high demand for safe and precise vascular remodeling tool

The first indication that LuSeed tackles is Cerebral aneurysms.

Providing the interventional vascular world with a novel, game changing approach to vascular closure, by:

A Platform Technology

The clinical need for full or partial blood vessel closure is indicated in a range of pathologies

Challenges in intrasaccular devices 

Difficult implantation procedures

Complex implant selection​

Up to 30 different size options

Risk for Protrusion

Release mechanism disturbs flow in the parent artery & causing thrombi

Inaccurate Deployment

High sensitivity to catheter tip location

Long-term risks for patients

50%

non-complete occlusion

11.4%

Retreatment rate

Lifetime Annual follow up

For com-complete occlusion cases

LuSeed intrasaccular device

A Nitinol braided mesh implant containing a composite core wire for visualization

Emitting local electromagnituc waves specifically at the aneurysmal volume

Acute treatment by immediate flow disruption & intensified thrombus Creation. Partition of aneurysm from parent blood vessel

Long term efficacy by enhancement of neo-intimal growth across mesh at neck and mature thrombosis inside the aneurysm

LuSeed’s Device Main benefits

Provides long term efficacy

No protrusion of release mechanism

Agnostic to direction of implantation

5 sizes only

Reduced procedural time

Fit’s in a 0.021” Microcatheter

LuSeed’s Team

Amir Arthur

Co-founder & CEO


Amir Arthur

Co-founder & CEO

Mechanical & Biomedical R&D Engineer
(M.E, Technion) 

Vast experience in percutaneous medical devices design with a deep knowledge of long-term vascular implants.
Highly experienced in strategy building & project management. 

Nitzan Hirsh

Co-founder & CTO


Nitzan Hirsh

Co-founder & CTO

Mechanical & Biomedical R&D Engineer 
(M.E, Technion) 

Extensive experience in multidisciplinary medical device systems design, development and management.

Deep knowledge in physical and physiological processes and analysis.

Moshe Miller

Mechanical Engineering Leader

Moshe Miller

  • Mechanical R&D leader
  • Managed the full life cycle of neurovascular medical products from concept to commercial launching.
  • Experience in optimizing design and production processes of commercial products

Dr. Efi Lavie

Active Element Process Development Leader

Dr. Efi Lavie

  • Radioisotope production project manager
  • Ex. Soreq’s nuclear facility head of Radio pharmacy unit
  • Ph.D in Radiochemistry
  • Vast experience in radioisotope R&D for the medical device and pharma industries

Shraga Ciner

Mechanical Engineer


Shraga Ciner

  • Mechanical R&D and Design Transfer engineer.
  • Holds extensive experience in production processes development for minimal invasive medical devices.

Contact Us